-
Methicillin Sodium Salt in MSSA Research
2026-09-12
Build reproducible MSSA susceptibility assays, gram-positive infection models, and resistance comparisons with Methicillin sodium salt. The workflow also shows how to connect phenotypic antibiotic data with target-focused screening without confusing MSSA activity with MRSA or Mycobacterium tuberculosis mechanisms.
-
Cefiderocol Activity Against Resistant Enterobacterales
2026-09-12
This multicountry European study evaluated cefiderocol against 1,909 Enterobacterales isolates, including organisms resistant to meropenem and established β-lactam/β-lactamase inhibitor combinations. Cefiderocol showed high in vitro susceptibility overall and retained activity against many highly resistant isolates, while genomic analysis linked cefiderocol resistance to combinations of iron-uptake, carbapenemase, and ftsI alterations.
-
Cinoxacin: In Vitro Findings from the 1975 Study
2026-09-11
The reference study established a systematic in vitro profile of Cinoxacin against clinical aerobic Gram-negative isolates, combining susceptibility testing, disk diffusion, bactericidal assays, and resistance selection. Its findings provide a historical evidence base for interpreting Cinoxacin MIC values and designing urinary tract infection research and antibiotic resistance studies.
-
Cy5 amine (non-sulfonated): Labeling Guide
2026-09-11
Cy5 amine (non-sulfonated), SKU A8143, provides a primary amino group for covalent attachment to activated biomolecules while offering red/far-red fluorescence near 662 nm. It must be dissolved in DMSO or ethanol before transfer into a compatible aqueous labeling workflow and is intended for research use, not diagnostic or medical applications.
-
Methicillin Sodium Salt as a Translational Benchmark
2026-09-10
A mechanistic and strategic guide to using Methicillin sodium salt as a benchmark for Staphylococcus aureus susceptibility, resistance biology, gram-positive infection models, and translational antibiotic development.
-
BHQ (2,5-di-tert-butylbenzene-1,4-diol) Workflow Guide
2026-09-10
Learn how BHQ converts SERCA inhibition into measurable calcium-store depletion, capacitative calcium entry, and pathway-level biology. This practical guide connects calcium signaling research with vascular physiology and the emerging HSC-mobilization application while emphasizing controls, workflow design, and troubleshooting.
-
Arachidonic Acid for Reproducible Cell Assays
2026-09-09
Learn how Arachidonic Acid (SKU C4223) can help researchers design more interpretable viability, proliferation, and inflammation assays. This scenario-based guide covers lipid signaling, solvent compatibility, concentration planning, data interpretation, and practical product selection.
-
Ceftolozane/Tazobactam: Evidence and Clinical Relevance
2026-09-09
The reference review examines ceftolozane/tazobactam as an antipseudomonal cephalosporin/β-lactamase inhibitor combination designed to address resistant gram-negative infections. Its principal contribution is an integrated analysis of antibacterial mechanisms, pharmacokinetics, pharmacodynamics, resistance, clinical trial evidence, dosing, and safety for complicated intraabdominal and urinary tract infections.
-
GlycoRNA–RBP Nanodomains and TAT Entry
2026-09-08
The reference preprint presents evidence that cell-surface RNA-binding proteins and glycoRNAs organize into extracellular nanoclusters that support entry of the cell-penetrating peptide TAT. Its perturbation-based design links surface RNA, cluster integrity, and peptide internalization, expanding conventional models of plasma-membrane organization while leaving the molecular anchoring mechanism open.
-
Haloprogin: Evidence from a 1970 Topical Antifungal Study
2026-09-08
The 1970 reference study established Haloprogin as a topical antifungal with dermatophyte activity comparable to tolnaftate, while identifying additional activity against Candida species and selected Gram-positive bacteria. Its combination of serial-dilution testing, fungicidal confirmation, and guinea pig infection models provides a useful evidence framework for contemporary dermatophytosis and topical antimicrobial research.
-
Camostat Mesilate: ENaC and Fibrosis Research
2026-09-07
Camostat Mesilate is a trypsin-like protease inhibitor used to study airway epithelial sodium channel regulation, plasmin activity, TGF-β signaling, and hepatic fibrosis. Product information reports an ENaC-related IC50 of 50 nM, while animal-model data support further investigation of plasmin inhibition and reduced hepatic stellate cell activation.
-
Baicalin Methyl Ester for Intestinal Barrier Research
2026-09-05
Baicalin methyl ester offers a focused workflow for studying inflammatory signaling and tight-junction recovery after epithelial barrier injury. Its defined concentration range, pathway-linked readouts, and formulation constraints make it useful for connecting MODE-K cell assays with mouse intestinal inflammation models.
-
Cinoxacin Workflow Guide for Gram-Negative Studies
2026-09-05
Build more reproducible susceptibility, kill-kinetic, and resistance experiments with Cinoxacin, a DNA synthesis-targeting quinolone antibiotic. This guide connects practical assay design with urinary tract infection research, bacterial prostatitis research, and structured troubleshooting for gram-negative aerobic bacteria.
-
Sodium dicloxacillin monohydrate: Assay Guide
2026-09-04
Sodium dicloxacillin monohydrate is a focused tool for MSSA and Gram-positive bacterial infection research. This guide connects β-lactam pharmacology with analytical assay selection, explaining how to interpret potency, compartment effects, formulation chemistry, and translational limitations.
-
Gepotidacin Versus Nitrofurantoin in UTI Trials
2026-09-04
The EAGLE-2 and EAGLE-3 phase 3 trials evaluated oral gepotidacin, also known as GSK2140944, against nitrofurantoin for uncomplicated urinary tract infection. Gepotidacin met the prespecified non-inferiority criterion in both studies and was superior to nitrofurantoin in EAGLE-3, supporting clinical development of an oral antibiotic with a distinct bacterial topoisomerase pathway target.